ZEVRA THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $623.18M
- P/E (TTM)
- 10.9
- Dividend yield
- –
About Zevra Therapeutics
Pharmaceutical Preparations, SIC 2834
Zevra Therapeutics, Inc. is a pharmaceutical company that develops and commercializes therapies for rare diseases. Its commercial products include MIPLYFFA for Niemann-Pick disease type C, OLPRUVA for urea cycle disorders, and AZSTARYS for attention deficit hyperactivity disorder, marketed through partners. The company also advances clinical candidates such as celiprolol for vascular Ehlers-Danlos syndrome and KP1077 for sleep disorders. Its products serve adult and pediatric patients with rare neurodegenerative, metabolic, and genetic conditions.
The company distributes products in the United States and provides MIPLYFFA in France, Germany, other European Union nations, and select global markets via an expanded access program. It is also seeking regulatory approval across the European Union. Partner agreements grant commercialization rights in European countries and Greater China. Furthermore, the company holds active patents across North America, Europe, Asia, and other territories. The excerpt does not mention the company's headquarters location.
Summary of the business section of Zevra Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ZEVRA THERAPEUTICS, INC.
- Headquarters
- Boston, MA
- Address
- 101 Federal Street 02110
- Phone
- (888) 958-1253
- Website
- zevra.com
- Employees
- 61, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Orlando, Florida
Stock & identifiers
- Ticker
- ZVRA
- Exchange
- Nasdaq
- IPO date
- Apr 16, 2015
- Shares outstanding
- 59M, Jul 31, 2026
- Public float
- $454.80M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-16 reverse, Mar 12, 2021; 1-for-16 reverse, Dec 28, 2020
- SEC CIK
- 1434647
- CUSIP
- 488445206
- ISIN
- US4884452065
- LEI
- 254900CU6T74V18Y1W18
- EIN
- 20-5894398
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Neil F. McFarlane | President and CEO, Director | 387,225 |
| Rahsaan Thompson | Chief Legal & Compliance | 37,569 |
| Timothy J. Sangiovanni | SVP, Finance & Corp Controller | 29,590 |
| Justin A. Renz | CFO | – |
| Joshua Schafer | CCO | 62,278 |
| Adrian W. Quartel | Chief Medical Officer | 14,256 |
| Corey Michael Watton | Director | 1,800 |
| Thomas Anderson | Director | 20,000 |
| Tamara A. Favorito | Director | 3,894 |
| Alicia Secor | Director | – |
| Alvin Shih | Director | 20,000 |
| Douglas W. Calder | Director | – |
| John B. Bode | Director | 123,400 |
| Wendy L. Dixon | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr.Mc Farlane | $3.78M | $4.00M | $2.70M | – | $195 |
| FY2024 Mr.Mc Farlane | $5.36M | $7.32M | $1.98M | – | $182 |
| FY2023 Christal M.Mickle | $1.67M | $2.21M | $2.04M | – | $143 |
| FY2023 Current CEO | $3.45M | $4.98M | $2.04M | – | $143 |
| FY2023 Former CEO1 | $3.59M | $4.39M | $2.04M | – | $143 |
| FY2023 Former CEO2 | $4.12M | $3.31M | $2.04M | – | $143 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 61 full-time employees.”
Corporate history
Events identified from SEC filings